{"id":"NCT02016560","sponsor":"Avid Radiopharmaceuticals","briefTitle":"Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects","officialTitle":"An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2013-12","primaryCompletion":"2017-07-28","completion":"2017-07-28","firstPosted":"2013-12-20","resultsPosted":"2020-08-24","lastUpdate":"2020-09-22"},"enrollment":383,"design":{"allocation":"NON_RANDOMIZED","model":"SEQUENTIAL","masking":"SINGLE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"florbetapir F 18","otherNames":["Amyvid","18F-AV-45"]},{"type":"DRUG","name":"Flortaucipir F18","otherNames":["T807","18F-AV-1451"]},{"type":"PROCEDURE","name":"Brain PET Scan","otherNames":[]}],"arms":[{"label":"Exploratory Cognitively Healthy Subjects","type":"EXPERIMENTAL"},{"label":"Exploratory MCI Subjects","type":"EXPERIMENTAL"},{"label":"Exploratory AD Subjects","type":"EXPERIMENTAL"},{"label":"Confirmatory Subjects","type":"EXPERIMENTAL"}],"summary":"A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).","primaryOutcome":{"measure":"Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline","timeFrame":"between baseline and 18 months","effectByArm":[{"arm":"Predicted to Progress","deltaMin":36,"sd":null},{"arm":"Not Predicted to Progress","deltaMin":31,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.067"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":15,"exclusionCount":9},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":["33587110"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Injection site pain","Headache","Blood pressure increased","Injection site extravasation","Angina pectoris"]}}